Shares of InMode (NASDAQ: INMD), a medical technology company focused on the aesthetics industry, recently reached a new 52-week high in anticipation of the second-quarter earnings report the company announced on Thursday, July 27.

InMode's pre-earnings rally drove the stock's 12-month performance up past 65%. After climbing to such heights, plenty of investors are wondering if it might already be too late to buy the stock.

Here's a look at InMode's recent performance and its place in the aesthetics industry to see if investors can reasonably expect more upside ahead.

Continue reading

Source Fool.com